"GLP-3 pen" refers to retatrutide supplied in a pre-filled research pen — in this catalogue the 60mg/3ml format. This covers what the compound actually is, how the pen compares to the lyophilised vial on cost and stability, and what to verify before buying. It does not cover use, because these are research materials and that would be a different kind of document.
Proxiva Handling & Storage DeskReconstitution, stability and laboratory practice
Key takeaways
- Retatrutide is a triple receptor agonist — it engages GLP-1, GIP and glucagon receptors, which is what distinguishes it from single- and dual-agonist compounds.
- "GLP-3" is a catalogue shorthand, not a receptor name. There is no GLP-3 receptor; the label distinguishes it from GLP-1 and dual-agonist products on the same shelf.
- The pen holds 60mg across 3ml, which is 20mg/ml, fixed at manufacture.
- Per milligram the vial is substantially cheaper; the pen buys measurement repeatability and skips reconstitution.
- It is a long peptide, so synthesis yield and deletion-sequence separation both make mass-spectrometry verification more important, not less.
What the name actually means
"GLP-3" is catalogue shorthand and it causes real confusion, so it is worth stating plainly: there is no GLP-3 receptor. The naming exists to separate products on a shelf, not to describe biology.
The incretin peptides that matter here are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Compounds in this class are described by how many receptors they engage:
| Class | Receptors engaged | Catalogue label here |
|---|---|---|
| Single agonist | GLP-1 | GLP-1 S / semaglutide |
| Dual agonist | GLP-1 + GIP | GLP-2 T / tirzepatide |
| Triple agonist | GLP-1 + GIP + glucagon | GLP-3 / retatrutide |
So the "3" counts receptors, not a receptor type. Retatrutide is the triple agonist — it engages the glucagon receptor in addition to the two the dual agonist covers.
Understanding this is useful commercially as well as scientifically, because it explains the price ladder across the three: each additional receptor target reflects a more complex molecule to design and synthesise.
The pen: what you are buying
The 60mg/3ml pen contains material already in solution at a fixed concentration. The arithmetic is straightforward — 60mg across 3ml is 20mg/ml, and it cannot be changed.
| Lyophilised vial | 60mg/3ml pen | |
|---|---|---|
| State on arrival | Dry powder | In solution |
| Concentration | You set it | Fixed 20mg/ml |
| Stability clock | Starts at reconstitution | Started at manufacture |
| Measurement | Syringe, operator-dependent | Dial, repeatable |
| Long storage | Better | Worse — it is a solution |
| Reconstitution error | Possible | Eliminated |
For this compound the stability row deserves weight. Retatrutide is a long peptide, and longer chains present more sites vulnerable to hydrolysis and oxidation than short ones do. Extended time in solution therefore costs more here than it would for a five-residue compound — and the fill date on a pen is frequently undisclosed.
Ask the supplier when the pen was filled. The willingness to answer is informative in itself. The general trade-offs are covered in pens versus vials.
There is also a full kit for researchers buying at volume, which prices differently again.
Cost per milligram, which is the only fair comparison
Pen and vial are quoted in different units, so sticker prices rank them wrongly. Convert both before deciding anything.
The pen states 60mg. The vial states its own fill. Divide price by milligrams in each case and compare the two numbers — that is the entire method, and it reorders supplier rankings more often than people expect.
Two adjustments make the comparison honest:
- Net peptide, not gross weight. HPLC purity measures only UV-absorbing organic material. Water and counterion are invisible to it, so a stated milligram figure is always more than the peptide it contains. Ask whether the number is net or gross.
- Transit conditions. Peptides degrade with heat exposure and the damage is cumulative and irreversible. Material that spent a week warm has lost value no discount recovers — and a pen, already in solution, is more exposed to this than sealed lyophilised powder.
Across the wider catalogue the same method applies to GLP-1 S, GLP-2 T, Tesamorelin and everything else. Full treatment in choosing a research peptide supplier.
Why a third receptor changes the molecule
The step from dual to triple agonist is not incremental, and understanding why explains the price difference and the synthesis difficulty.
A receptor agonist has to fit a binding site. Designing one molecule that fits two related sites is already demanding, because the sequence has to satisfy both without being optimal for either. Adding a third target means satisfying three sets of structural constraints simultaneously with a single chain.
The glucagon receptor is the addition that makes retatrutide a triple agonist, and it is the least closely related of the three. GLP-1 and GIP receptors belong to the same family and share meaningful structural similarity; the glucagon receptor sits further away. A molecule engaging all three is threading a narrower needle than one engaging the two similar ones.
That constraint shows up in the finished molecule as a longer, more heavily modified chain — which is precisely what makes it expensive to synthesise. Every additional residue costs yield, and non-standard modifications add steps that each carry their own efficiency penalty.
It also has a verification consequence worth knowing. Modified residues and non-standard linkages mean the theoretical mass is not something you can calculate from a plain amino-acid sequence. A supplier reporting mass-spectrometry data should be comparing against the correct modified mass, and a certificate that reports a bare "sequence" the way it would for a simple peptide has probably been generated from a template rather than from analysis of this molecule.
The same reasoning applies down the ladder to the dual agonist and the single agonist — each is a different synthesis problem, and their prices reflect that rather than reflecting scarcity.
What should you ask for before ordering?
Three questions, and the answers tell you almost everything.
"Which laboratory ran this, and did they make the peptide?" A named lab that is independent of the synthesis is worth more than a purity figure from the facility that has a stake in the number. If a supplier cannot name the lab, there is nothing to weigh.
"Can I see the trace, not just the percentage?" This matters more here than for a short peptide. A long chain generates more failed couplings, and each failure leaves behind a chain missing one residue. Those sit close to the real molecule on a chromatogram. Several peaks bunched near the main one means the purification did not fully separate them; one clean peak with little shouldering means it did. A percentage flattens that distinction away entirely.
"Is the certificate for the filled pen or the bulk powder?" Almost every pen in this market is documented against the powder it was made from. That document describes what went in, not what came out, and says nothing about the filling itself. Ask which one you are being shown.
Beyond those three: batch number matching the label, mass spectrometry rather than purity alone, and figures for water and counterion content so you know how much of the stated weight is actually peptide. Our certificate guide works through every field.
Storage and handling
The pen removes the reconstitution step, which is where most avoidable handling loss occurs — but it does not remove the storage requirements.
- Refrigerate, protected from light
- Do not freeze a pen; it contains solution, and freeze-thaw damage is cumulative and invisible
- Note the date received, since the fill date is usually unknown
- Minimise time at room temperature during handling
For the lyophilised vial the ordinary discipline applies: sealed vial cold, dry and dark; reach room temperature before opening; reconstitute with bacteriostatic water for any vial punctured more than once; run diluent down the wall rather than onto the powder; swirl rather than shake; refrigerate and label afterwards; never re-freeze.
Procedures and the reasoning behind them are in reconstituting research peptides and storage and stability.
Other pre-filled formats in the catalogue include BPC-157, TB-500, MOTS-c, Melanotan II, GLOW and KLOW, alongside vials of BPC-157, TB-500, Ipamorelin, GHK-Cu, NAD+ and Epithalon.
Research use only
Why does this page say nothing about how much to use, or what to expect?
Because it cannot, honestly. Research compounds have no approved indication in that form, so any figure would be invention rather than guidance.
It is also worth knowing what that omission signals when you see it elsewhere. A supplier that publishes quantities and describes results for research-use-only material is asserting something it has no basis for — and regulators in this market have acted on exactly that pattern, in writing, naming firms. So the absence of that content is not squeamishness. It is the difference between a research supplier and something wearing the costume.
Read a catalogue on that basis and it sorts itself quickly.
Frequently asked questions
What does GLP-3 mean?
It is catalogue shorthand, not a receptor name — there is no GLP-3 receptor. The number counts receptors engaged: single agonist (GLP-1), dual (GLP-1 + GIP), triple (GLP-1 + GIP + glucagon). GLP-3 denotes the triple agonist, retatrutide.
How much is in the pen?
60mg across 3ml, which is 20mg/ml, fixed at manufacture and not adjustable.
Is the pen or the vial better value?
Per milligram the vial is substantially cheaper. The pen buys measurement repeatability and removes the reconstitution step. Convert both to cost per milligram before deciding.
Why does chain length affect verification?
Synthesis yield compounds across coupling steps, so longer peptides produce more deletion sequences — chains missing one residue. Those co-elute with the target, so mass spectrometry and the chromatogram matter more than the purity percentage alone.
What should a pen's certificate show?
Everything a vial's should, plus a certificate corresponding to the filled lot rather than only the bulk synthesis lot. A certificate for the powder before filling says nothing about filling.
Can the pen be frozen?
No. It contains material in solution, and freeze-thaw cycling causes cumulative damage that is not visible on inspection. Refrigerate and protect from light.
Related research compounds
Further reading
Research use only. All products referenced on this page are sold strictly for laboratory and research purposes. They are not drugs, foods, cosmetics, or medical devices, and they are not intended to diagnose, treat, cure, or prevent any disease. They are not for human or veterinary consumption. Handling should be performed only by qualified individuals in an appropriate laboratory setting.